Semaglutide

Introduction Overview

Generic Name

semaglutide

Brand Name

Wegovy

Dosage Form

pen injection, for subcutaneous use (0.25 mg pen, 0.5 mg pen, 1 mg pen, 1.7 mg pen, 2.4 mg pen)

Drug Class

GLP-1 Agonists (Incretin Mimetics)

Pharmacokinetics

Absorption:
Semaglutide, the active ingredient in Wegovy, is administered subcutaneously and exhibits gradual and sustained absorption. Following a single subcutaneous injection, the time to reach maximum plasma concentration (Tmax) is approximately 1 to 3 days. Its bioavailability through subcutaneous administration is consistently high, allowing predictable systemic exposure. The slow absorption contributes to its prolonged half-life, enabling once-weekly dosing. The absorption profile is not significantly altered by factors such as age, gender, or ethnicity.

Distribution:
Once absorbed, semaglutide is extensively bound to plasma albumin (>99%), which facilitates its prolonged half-life of approximately 7 days and stable plasma concentrations. The volume of distribution at steady state is large, indicating extensive tissue distribution, especially to GLP-1 receptor-rich organs such as the pancreas and brain. Limited penetration of the blood-brain barrier has been observed, but sufficient central nervous system exposure occurs to mediate appetite suppression. No significant binding to red blood cells or accumulation in adipose tissue has been reported.

Metabolism:
Semaglutide undergoes slow proteolytic degradation via general protein catabolic pathways, rather than cytochrome P450 enzyme metabolism. It is metabolized primarily by proteolytic cleavage of the peptide backbone and sequential beta-oxidation of the fatty acid side chain. Unlike many small-molecule drugs, semaglutide’s metabolic pathways bypass liver cytochrome P450 enzymes, minimizing classic drug-drug interactions. Major metabolites have no pharmacologic activity and are excreted in urine and feces.

Elimination:
The elimination of semaglutide is primarily through metabolic degradation into small peptides, amino acids, and fatty acid components, which are then excreted via renal and fecal routes. The drug’s half-life of about 7 days supports once-weekly administration, with steady state achieved after 4 to 5 weeks of dosing. Renal impairment has a minimal effect on semaglutide’s elimination, and dose adjustment is generally not required for mild to moderate kidney dysfunction, but data in severe renal impairment is limited. Hepatic impairment similarly has no significant effect on pharmacokinetics. No active drug accumulation has been observed with long-term use.

Dosage Forms

Available Dosage Forms:
Wegovy is available as a single-dose, pre-filled injection pen for subcutaneous use. The pen devices contain semaglutide at the following strengths:
- 0.25 mg/pen (4 pens per carton)
- 0.5 mg/pen (4 pens per carton)
- 1 mg/pen (4 pens per carton)
- 1.7 mg/pen (4 pens per carton)
- 2.4 mg/pen (4 pens per carton)

Dosages for Adults and Adolescents:
The dosing regimen is designed to mitigate gastrointestinal side effects by gradual escalation:
- Initial dose: 0.25 mg subcutaneously once weekly for 4 weeks
- Increase to 0.5 mg once weekly for the next 4 weeks
- Titrate to 1 mg once weekly for 4 weeks
- Further increase to 1.7 mg once weekly for 4 weeks
- Maintenance dose: 1.7 mg or 2.4 mg once weekly thereafter

In adults, if adverse effects prevent escalation, dose increases may be delayed or the maintenance dose may be reduced. In adolescents aged 12 years and older, the dose escalation schedule mirrors adults, but maintenance dosing is typically 2.4 mg once weekly. If 2.4 mg is not tolerated, reduction to 1.7 mg once weekly is considered; discontinuation is recommended if 1.7 mg is not tolerated.

Specific Patient Populations:
- Pediatric Use: Approved for patients 12 years and older with obesity, following the adult titration and maintenance protocol tailored for tolerability.
- Renal Impairment: No dose adjustment recommended for mild to moderate renal impairment; caution in severe impairment due to limited data.
- Hepatic Impairment: No dose adjustment needed.
- Elderly: Pharmacokinetics similar across age groups; no special dosing required.
- Pregnancy and Lactation: Not recommended; discontinue at least two months before planned pregnancy.

Administration Instructions:
Wegovy should be injected subcutaneously into the abdomen, thigh, or upper arm, rotating injection sites, and using a once-weekly schedule at a consistent day each week. The pen injection device delivers the dose with audible clicks; the needle must remain inserted until the dose is fully delivered. The medication can be administered with or without food.

Mechanism Of Action

Wegovy’s active ingredient, semaglutide, is a glucagon-like peptide-1 (GLP-1) receptor agonist, mimicking the activity of endogenous GLP-1, an incretin hormone. Normally, GLP-1 is released from intestinal L-cells in response to nutrient ingestion and plays a critical role in glucose homeostasis and appetite regulation. Semaglutide binds to the GLP-1 receptors located on pancreatic beta cells, gastrointestinal tract, and regions of the central nervous system involved in hunger and satiety.

At the cellular level, semaglutide’s binding to the GLP-1 receptor activates adenylate cyclase through G protein coupling, elevating intracellular cyclic AMP (cAMP) levels. This enhances insulin secretion in a glucose-dependent manner, thereby minimizing hypoglycemia risk. Concurrently, GLP-1 receptor activation suppresses glucagon secretion from pancreatic alpha cells, contributing to improved glycemic control. Additionally, semaglutide delays gastric emptying by modulating gastric motility through vagal nerve pathways, which prolongs postprandial fullness and reduces hunger sensations.

Crucially for weight management, GLP-1 receptors in key brain regions, such as the hypothalamus and brainstem, mediate the regulation of appetite and energy intake. Semaglutide’s activation of these receptors reduces appetite by enhancing satiety signals and decreasing hunger drive. This central effect leads to decreased caloric intake and subsequent weight loss. The compound’s long half-life allows sustained receptor activation, fostering consistent appetite suppression.

Comparatively, while other GLP-1 receptor agonists (like liraglutide and dulaglutide) share similar mechanisms, semaglutide has a higher receptor binding affinity and prolonged half-life, yielding more potent effects on glycemic control and weight reduction. Clinical trials have demonstrated that semaglutide induces more significant weight loss than earlier GLP-1 analogues. Ongoing research explores the molecular pathways involved, including potential modulation of reward pathways influencing eating behavior. Overall, semaglutide offers a multifaceted mechanism that combines metabolic and central nervous system actions to facilitate effective long-term weight management and cardiovascular risk reduction.

Pharmacological Actions

GLP-1 receptor agonism leading to enhanced glucose-dependent insulin secretion
Suppression of glucagon secretion to improve glycemic control
Delay of gastric emptying reducing postprandial glucose spikes and prolonging satiety
Central nervous system-mediated appetite suppression via hypothalamic receptors
Reduction in energy intake contributing to weight loss
Improvement of cardiovascular risk profile through weight reduction and direct receptor effects
Reduction of major adverse cardiovascular events in high-risk obese or overweight patients
Promotion of long-acting incretin mimetic activity with once-weekly dosing
Minimal risk of hypoglycemia when used as monotherapy due to glucose-dependent mechanism
Modulation of gastric motility to reduce hunger and promote fullness sensations
Anti-obesity effects demonstrated in both adult and adolescent populations
Potential neuroprotective effects under investigation in experimental models
Reduction of body fat mass and preservation of lean muscle mass when combined with lifestyle changes
Regulation of energy homeostasis at multiple organ system levels
Stabilization of blood sugar levels through combined pancreatic and gastrointestinal actions

Therapeutic Or Clinical Uses

Treatment of obesity in adults and adolescents aged 12 years and older
Weight management in overweight patients with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia
Long-term maintenance of clinically significant weight loss alongside lifestyle interventions
Reduction of cardiovascular risk, including lowering incidence of myocardial infarction, stroke, and cardiovascular death in obese or overweight adults with established cardiovascular disease
Adjunctive therapy to reduced-calorie diet and increased physical activity for sustainable weight control
Management of metabolic syndrome components through weight reduction
Potential improvement of glycemic control in type 2 diabetic patients with concomitant obesity (though not primarily indicated for diabetes with Wegovy formulation)
Support for reduction of insulin resistance mediated via weight loss
Intervention for patients unable to achieve weight loss through lifestyle modification alone
Part of multidisciplinary approach to obesity treatment involving behavioral and pharmacologic strategies
Reduction of cardiovascular events risk independent of glucose lowering
Adjunct therapy to prevent weight regain following initial weight loss
Support for weight loss in high cardiovascular risk populations
Useful in managing obesity-related complications by addressing root cause of excess adiposity
Adjunctive pharmacologic therapy approved by FDA for obesity and cardiovascular risk reduction

Side Or Adverse Effects

Nausea (experienced by approximately 44% of patients, typically during dose escalation)
Diarrhea (about 30% incidence in clinical trials)
Vomiting (occurring in approximately 24% of users)
Constipation (reported by around 24% of patients)
Abdominal pain or stomach discomfort (20%)
Headache (14%)
Fatigue or tiredness (11%)
Indigestion or dyspepsia (9%)
Bloating and flatulence (about 6-7%)
Heartburn (5%)
Low blood sugar (hypoglycemia), especially in patients with type 2 diabetes or on insulin therapy (6%)
Gastroenteritis symptoms including vomiting and diarrhea
Gallbladder disease (including cholelithiasis and cholecystitis)
Pancreatitis, marked by severe abdominal pain and nausea
Increased heart rate (tachycardia)
Serious allergic reactions such as angioedema and anaphylaxis
Potential thyroid tumors as seen in animal studies; unknown clinical significance in humans
Injection site reactions, including redness, bruising, or tenderness
Suicidal ideation or behavioral changes reported in limited cases
Fluid retention or worsening of kidney function in predisposed individuals

Precautions

Use cautiously in patients with a history of pancreatitis or pancreatic disease
Monitor for signs of gallbladder disease during treatment
Advise patients to report persistent gastrointestinal symptoms especially abdominal pain, nausea, or vomiting
Adjust dose or discontinue in case of intolerable gastrointestinal side effects
Avoid use in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
Consider gradual dose escalation to minimize gastrointestinal adverse effects
Exercise caution in patients with renal impairment; monitor kidney function regularly
Inform patients about the risk of hypoglycemia if used with insulin or insulin secretagogues
Evaluate mental health status due to reports of depression and suicidal thoughts
Ensure patients understand the importance of rotating injection sites to reduce local reactions
Stop therapy at least two months prior to planned pregnancy due to potential fetal risk
Exclude diabetic ketoacidosis before initiating therapy
Educate patients on promptly reporting signs of allergic reactions
Avoid use in pediatric patients under 12 years due to lack of safety data
Monitor heart rate and signs of cardiovascular events during treatment
Advise patients against sharing injection pens to prevent infection transmission

Warnings

Risk of thyroid C-cell tumors observed in rodent studies; human risk unknown
Contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2
Potential serious allergic reactions including anaphylaxis
Risk of pancreatitis; monitor for symptoms such as severe abdominal pain radiating to the back with nausea or vomiting
Gallbladder disease risk including cholelithiasis and cholecystitis
Hypoglycemia risk especially when combined with insulin or other hypoglycemics
Possible increased heart rate and cardiovascular effects requiring monitoring
Avoid use during pregnancy due to potential risk of harm to fetus; discontinue at least two months prior to conception
Possible gastrointestinal adverse reactions leading to dehydration or electrolyte imbalance
May cause suicidal ideation or depression; monitor patients with psychiatric history
Aspiration risk during anesthesia or deep sedation owing to delayed gastric emptying
Not studied nor recommended for use in severe renal or hepatic impairment
Injection site reactions including lipodystrophy or irritation
Do not use interchangeably with other semaglutide-containing products or GLP-1 receptor agonists for different indications
Use with caution when co-administered with other medications affecting gastric motility

Contraindication

Known hypersensitivity or allergy to semaglutide or any formulation component
Personal or family history of medullary thyroid carcinoma (MTC)
Multiple endocrine neoplasia syndrome type 2 (MEN 2)
Patients with a history of pancreatitis unless benefits outweigh risks
Use in patients with diabetic ketoacidosis
Pregnant women or those planning pregnancy within two months
Pediatric patients under 12 years due to lack of safety data
Severe gastrointestinal disease with gastroparesis
Severe renal impairment or end-stage renal disease (caution advised)
Severe hepatic impairment (no established safety)
History of serious hypersensitivity reactions to GLP-1 receptor agonists
Use in combination with other GLP-1 receptor agonists or semaglutide products for diabetes
Concurrent use with drugs contraindicated due to drug interaction potential
Patients with active gallbladder disease unless treated and stable
Patients with unstable cardiac conditions without careful monitoring

Drug Interactions

May slow gastric emptying, potentially delaying absorption of oral medications
Concomitant use with insulin or insulin secretagogues (e.g., sulfonylureas) increases risk of hypoglycemia
No significant cytochrome P450 enzyme interactions due to peptide metabolism
Potential interaction with other GLP-1 receptor agonists leading to additive effects or adverse reactions
Medications requiring rapid onset or narrow therapeutic windows (e.g., oral contraceptives, antibiotics) may be affected by slowed gastrointestinal motility
Possible altered absorption of vitamins and herbal supplements due to delayed gastric emptying
Interactions with anticoagulant therapy have not been extensively studied; monitor for bleeding
Use with caution alongside drugs affecting heart rate or blood pressure due to possible additive cardiovascular effects
May interact with medications metabolized by non-P450 pathways; clinical significance uncertain
No known interaction with diuretics or statins, but monitoring recommended as weight loss modifies metabolic state
Recommendations to monitor blood glucose closely when combined with diabetes medications
Avoid use with other appetite suppressants to prevent overlapping adverse effects
No known interaction with vaccination efficacy but data limited
Some herbal products may alter glucose metabolism; consult healthcare provider
Patient counseling to discuss all concomitant medications including OTC and supplements

Preparations Of The Drug

Semaglutide active ingredient
Inactive ingredients including disodium phosphate dihydrate
Contains sodium chloride for isotonicity
Water for injection as solvent
Formulated in a ready-to-use, single-dose, prefilled injection pen
Pens available in multiple strengths: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg per injection
Pen device includes concealed needle with safety features to prevent needle-stick injury
Packaging includes carton with four single-dose pens
Storage instructions requiring refrigeration between 2°C to 8°C (36°F to 46°F)
Stable at room temperature (8°C to 30°C) for up to 28 days after removal from the refrigerator before first use
Packaged with instructions for single-use and disposal into FDA-approved sharps containers
Manufactured by Novo Nordisk A/S, Denmark
Developed with patient-friendly delivery system for weekly self-administration
Supplied with training materials and patient guides
Compliant with regulatory standards for sterility and stability